हिंदी में पढ़ें

Lupin

Lupin gets 6 observations from USFDA for Pithampur plant

Lupin gets 6 observations from USFDA for Pithampur plant

Sat, Sep 28, 2024

The US Food and Drug Administration (USFDA) inspected the company's Pithampur Unit-1 API and finished product manufacturing facility from September 16 to September 27, 2024.

Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market

Lupin signs patent licence pact with Takeda for novel gastrointestinal drug in Indian market

Wed, Sep 18, 2024

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialise Vonoprazan in India.

Sunsure Energy to supply 21 MW solar power to Lupin

Sunsure Energy to supply 21 MW solar power to Lupin

Fri, Sep 13, 2024

Sunsure Energy and Lupin Ltd announced the signing of a 21 MW (31.5 MWp) solar Open Access Power Purchase Agreement (PPA).

TRENDING NOW

Stock of The Day: Today Anil Singhvi gave buying advice in Lupin

Stock of The Day: Today Anil Singhvi gave buying advice in Lupin

Thu, Aug 08, 2024

Stock of The Day: Today Anil Singhvi gave buying advice in Lupin. What are stoploss and targets? See in this video.

Global brokerages bullish on Lupin a day after its con call; check out target

Global brokerages bullish on Lupin a day after its con call; check out target

Thu, Aug 08, 2024

On Tuesday, after market hours, pharma major Lupin reported a 77 per cent increase in consolidated net profit at Rs 801 crore for the first quarter ended June 30, 2024, aided by robust sales across markets.

Lupin Q1 FY25 Results Preview: Net profit likely to grow by one-third, margin may improve by 200 bps; here is what else you can expect

Lupin Q1 FY25 Results Preview: Net profit likely to grow by one-third, margin may improve by 200 bps; here is what else you can expect

Tue, Aug 06, 2024

Lupin Q1 FY25 Results Preview: Mumbai-headquartered drug maker Lupin is estimated to register a 30 per cent year-on-year jump in its consolidated net profit for the April-June period. Read on to know what else you can expect in the pharmaceutical company's upcoming earnings report.

Lupin ties up with South Korea-based Huons

Lupin ties up with South Korea-based Huons

Thu, Jul 18, 2024

Mumbai-based Lupin has signed a license and supply agreement with Huons for the registration and marketing of Cyclosporine Ophthalmic Nanoemulsion (0.4mL single-use vial) in Mexico.

Lupin gets USFDA nod for generic medication

Lupin gets USFDA nod for generic medication

Fri, Jul 12, 2024

Topiramate extended-release capsules are indicated for the treatment of seizures in patients six years of age and older.

Lupin shares gain on Dalal Street—here's why

Lupin shares gain on Dalal Street—here's why

Mon, Jun 24, 2024

Lupin share price: Lupin shares gained nearly two per cent to the day's high of Rs 1,590 on NSE in morning deals, halting the nine-day declining trend.

Lupin, Eugia recall products from US market: USFDA

Lupin, Eugia recall products from US market: USFDA

Sun, Jun 23, 2024

Baltimore-based Lupin Pharmaceuticals Inc is recalling 3,552 bottles of Cefixime for Oral Suspension (USP 200 mg/5 mL) due to "failed content uniformity specifications".

5 stocks to buy for up to 28% returns in 1 year - Check targets

5 stocks to buy for up to 28% returns in 1 year - Check targets

Tue, Jun 11, 2024

Stocks to Buy: Prime Minister Narendra Modi has retained four high-profile ministries in his new government. It may help the implementation of projects faster. Amid this, brokerage firm Sharekhan has picked five stocks with strong fundamentals.

Lupin recalls 51k bottles of generic antibiotic drug in US

Lupin recalls 51k bottles of generic antibiotic drug in US

Sun, Jun 09, 2024

The US-based arm of the drug maker is recalling 51,006 bottles of Cefdinir for Oral Suspension (250 mg/5 mL) due to "defective container: lack of seal integrity," US Food and Drug Administration (USFDA) said in its latest Enforcement Report.

Drug-maker Lupin completes acquisition of two brands from Sanofi

Drug-maker Lupin completes acquisition of two brands from Sanofi

Wed, Jun 05, 2024

Shares of Lupin were trading 3.21 per cent higher at Rs 1,613.45 apiece on the BSE.

Lupin's PAT misses estimates; management confident of FY 25; should you buy, sell or hold?

Lupin's PAT misses estimates; management confident of FY 25; should you buy, sell or hold?

Tue, May 07, 2024

Lupin share price: Total revenue from operations rose to Rs 4,961 crore in the period under review as compared with Rs 4,430 crore in the same period last fiscal, Lupin said in a regulatory filing.

Lupin Q4 Results Preview: Net profit likely to more than double, margin may expand by 700 bps

Lupin Q4 Results Preview: Net profit likely to more than double, margin may expand by 700 bps

Mon, May 06, 2024

Lupin Q4 FY24 Results Preview: Mumbai-headquartered Lupin is expected to report a net profit of Rs 559 crore for the January-March period, more than double over a net profit of Rs 236 crore for the corresponding period a year ago, according to Zee Business research.

8 large- and mid-cap pharma stocks that have more than doubled in a year

8 large- and mid-cap pharma stocks that have more than doubled in a year

Fri, Apr 26, 2024

Wockhardt, Lupin, Jubilant Pharma, Concord Biotech and Shilpa Medicare have been some of the top pharma stocks in the 1-year period.

Lupin gets USFDA nod for generic eye treatment drug

Lupin gets USFDA nod for generic eye treatment drug

Thu, Apr 25, 2024

The company has received approval from the US Food and Drug Administration (USFDA) to market Etabonate Ophthalmic Suspension, the Mumbai-based drug maker said in a statement.

Lupin rises after US FDA gives pharma firm EIR for its Aurangabad facility

Lupin rises after US FDA gives pharma firm EIR for its Aurangabad facility

Wed, Apr 24, 2024

Lupin said on Tuesday that it had received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Aurangabad manufacturing facility. The inspection was conducted from March 6 to March 15, 2024. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

Explosive Surge in Lupin's & zydus Shares - What News Drove to Action?

Explosive Surge in Lupin's & zydus Shares - What News Drove to Action?

Mon, Apr 22, 2024

Strong rise in Lupine's shares - What news made Zydus Life run away? Where is the rise in Lupine, Zydus Life coming from? Which medicine launched in America? - Know complete details in this video...

Drug maker Lupin launches Mirabegron extended-release tablets in US market

Drug maker Lupin launches Mirabegron extended-release tablets in US market

Mon, Apr 22, 2024

The Mumbai-based drug maker Lupin has introduced the medication after receiving an approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.

Lupin, Glenmark recall drugs in US market: USFDA

Lupin, Glenmark recall drugs in US market: USFDA

Wed, Apr 10, 2024

As per the latest Enforcement Report by the US Food and Drug Administration (USFDA), Lupin is recalling 26,352 bottles of Rifampin Capsules (300 mg), an antibiotic medication in the US market.

Lupin gets nod to launch Doxycycline capsules from USFDA; stock rises

Lupin gets nod to launch Doxycycline capsules from USFDA; stock rises

Wed, Apr 10, 2024

On Tuesday (April 9), the company, through a regulatory filing, informed investors that the US Food and Drug Administration (US FDA) had given the company approval to launch the first generic version of Oracea.

Lupin gets USFDA nod for generic antibacterial drug

Lupin gets USFDA nod for generic antibacterial drug

Fri, Mar 15, 2024

The company's product is the generic equivalent of Pfizer Inc's Vibramycin for injection, it added.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x